Novartis $12 Billion Bet on Avidity Is Starting to Pay Off -- Market Talk
Dow Jones
Jun 11
0834 GMT - Novartis's results of an early and midstage study for a neuromuscular-disease drug candidate suggest its $12 billion acquisition of Avidity is starting to pay off, Jefferies says. The study for the drug, del-brax, in the treatment of rare genetic disease facioscapulohumeral muscular dystrophy met the primary goal and reduces risk on the technology platform the Swiss drugmaker acquired through the Avidity deal to some extent, Jefferies says. Still, the main proof point for the Avidity acquisition will be a late-stage study for another drug, del-desiran, in myotonic dystrophy type 1, according to Jefferies. Novartis shares trade 0.15% higher. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
June 11, 2026 04:34 ET (08:34 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.